EyeGene KRX:185490KOSDAQ
아이진 · Korean news coverage and regulatory filings, organized.
In Q3 2026, EyeGene reported revenue of ₩1.2bn, up 6.1% year on year, and an operating loss of ₩2.5bn. EyeGene (아이진) appeared in 2 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Nov 10 with 1 article. It was most often mentioned alongside EG and Daesang.
Filing signals Insider buying Major holder adding Clinical trial filing 4 quarters of losses Screener
EyeGene at a glance from DART filings
- Results trend
- Operating loss in each of the last 4 quarters; Q3 2026 operating loss of ₩2.5bn a loss again after the previous quarter.
- Ownership changes
- 3 5%-holder and insider ownership reports in the past 120 days (3 increases, 0 decreases).
Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.
EyeGene today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates EyeGene stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
EyeGene quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩1.2bn | +6.1% | −₩2.5bn margin −215.2% | −₩2.3bn |
| Q2 2026 | ₩1.3bn | +52.7% | −₩3.9bn margin −294.8% | −₩3.8bn |
| Q1 2026 | ₩1.3bn | +55.6% | −₩3.5bn margin −277.7% | −₩3.6bn |
| Q4 2025 derived | ₩774m | -41.0% | −₩3.3bn | −₩12.1bn |
| Q3 2025 | ₩1.1bn | +14.4% | −₩1.6bn margin −150.1% | −₩1.6bn |
| Q2 2025 | ₩877m | +56.3% | −₩2.5bn margin −279.6% | −₩2.5bn |
| Q1 2025 | ₩818m | +56.3% | −₩2.5bn | −₩3.0bn |
| Q4 2024 derived | ₩1.3bn | +8.1% | −₩2.4bn margin −180.8% | −₩2.7bn |
EyeGene ranks #2026 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
EyeGene top stories 2 weeks, by number of outlets
- 1
- 2
Latest EyeGene news Korean headlines
-
MajorI-Gene Consortium begins phase 1 human dosing of coronavirus mRNA vaccine candidate
5 more on this story · 5 outlets
- iGene consortium begins phase 1 clinical trials of domestic coronavirus mRNA vaccine메디컬투데이 · Oct 29 09:12
- Aizin Consortium begins phase 1 dosing for COVID-19 mRNA vaccine이투데이 · Oct 29 09:14
- Ajin announces consortium Covid-19 vaccine phase 1 vaccination start뉴시스경제 · Oct 29 09:33
- Ajin Consortium begins Phase 1 clinical trial of Covid mRNA vaccine머니투데이 · Oct 29 09:40
- Ajin Consortium begins phase 1 clinical administration for domestic coronavirus mRNA vaccine뉴스1 · Oct 29 16:56
-
I-Gene starts first human dosing of domestic coronavirus mRNA vaccine...targets phase 2 next year
3 more on this story · 3 outlets
- I-Gene Consortium begins clinical phase 1 dosing of domestic coronavirus mRNA vaccine바이오타임즈 · Oct 29 08:38
- Aijin consortium gives first injection of domestic COVID-19 mRNA vaccine...pursues phase 2 next yearPRESS9 · Oct 29 09:40
- Aijin starts clinical phase 1 for homegrown coronavirus mRNA vaccine, targets phase 2 next year한스경제 · Oct 29 10:02
-
Aigene building Ailia factory in eye; enters phase 1 and 2a clinical trials next year
1 more on this story · 1 outlets